About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
Nonmalignant Hematology
Malignant Hematology
Updates in Oncology
Breast Cancer Updates
Events
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
DVT/PE: Full-Dose or Intermediate-Dose DOAC?
By
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
FEATURING
Stephan Moll
By
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
FEATURING
Stephan Moll
157 views
December 17, 2020
0 Comments
Login to view comments.
Click here to Login
Nonmalignant Hematology
06:25
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
DVT/PE: Full-Dose or Intermediate-Dose DOAC?
Feat.
S. Moll
13:54
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
DVT/PE: What is the Optimal Duration of Anticoagulation with DOACs l…
Feat.
S. Moll
11:29
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
Oral Anticoagulant Therapy: How Can We Improve on Existing Oral Anti…
Feat.
J. Eikelboom
10:02
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
Oral Anticoagulant Therapy: What are the Unmet Needs?
Feat.
J. Eikelboom
25:59
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
Approach to Thrombocytopenia in the Hospitalized Patient
Feat.
J. Kelton
17:54
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
Key Concept of Heparin-induced Thrombocytopenia in 2020: Approach &a…
Feat.
J. Kelton
21:26
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
Case of 54/m With Thrombotic Microangiopathy: Differentiating TTP an…
Feat.
S. Chaturvedi
14:03
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
Role of Complement Activation in HELLP and CAPS & Complement in …
Feat.
S. Chaturvedi
20:32
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
Algorithms to Minimize Bleeding in At Risk Patient Populations on An…
Feat.
J. Green
10:10
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
Considerations on Oral Anticoagulant Use After Bariatric Surgery &am…
Feat.
J. Green
24:44
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
Diagnosis of Waldenstrom Macroglobulinemia: MYD88 Mutation Status, I…
Feat.
M. Gertz
18:52
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
Treatment of Waldenstrom Macroglobulinemia: Bendamustine Based Thera…
Feat.
M. Gertz
36:18
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
Understand Principles of Diagnosing Von Willebrand Disease and Its S…
Feat.
A. Ma
07:08
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
Difficulties in Testing for Von Willebrand Disease & Treatment O…
Feat.
A. Ma
05:55
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
VTE in Cancer: Risk Factors, DOACS are Reasonable Choice, Less Recur…
Feat.
S. Moll
20:20
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
DVT/PE: Duration of Anticoagulation, Full-Dose or Intermediate-Dose …
Feat.
S. Moll
13:35
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
DOAC Update: Use in Obese Pts, DOAC vs VKA, APS and DOACs
Feat.
S. Moll
05:33
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
54 y/o Man on Long-term Rivaroxaban Needs Screening Colonoscopy: Whe…
Feat.
S. Moll
17:39
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
Challenges of Anticoagulant Selection, Dosing, and Administration in…
Feat.
M. Pai
14:36
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
Monitoring, Interrupting, Reversing Anticoagulants, Management of DO…
Feat.
M. Pai
23:45
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
Oral Anticoagulant Therapy: Unmet Needs & Improving on Existing …
Feat.
J. Eikelboom
11:34
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
Are There Ways Other Than Directly Targeting Coagulation to Reduce t…
Feat.
J. Eikelboom